The burkholderia pseudomallei enoyl-acyl carrier protein reductase fabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 931-935

  Cummings, Jason E ^a   Kingry, Luke C ^a   Rholl, Drew A ^a   Schweizer, Herbert P ^a   Tonge, Peter J ^b   Slayden, Richard A ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); OFLOXACIN; PROTEIN FABI; PROTEIN FABI1; PROTEIN FABV; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FATTY ACID SYNTHESIS; FEMALE; IN VIVO STUDY; KNOCKOUT MOUSE; MELIOIDOSIS; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BURKHOLDERIA PSEUDOMALLEI; ENOYL-(ACYL-CARRIER PROTEIN) REDUCTASE (NADPH, B-SPECIFIC); ENZYME INHIBITORS; FEMALE; GENE KNOCKOUT TECHNIQUES; ISOENZYMES; MELIOIDOSIS; MICE; MUTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84893492498     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00176-13     Document Type: Article

References (41)

1. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416. http://dx.doi.org/10.1128/CMR. 18.2.383-416.2005.
2. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4:272-282. http://dx.doi.org/10.1038/nrmicro1385.
3. Lazar Adler NR, Govan B, Cullinane M, Harper M, Adler B, Boyce JD. 2009. The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease? FEMS Microbiol. Rev. 33: 1079-1099. http://dx.doi.org/10.1111/j.1574-6976.2009.00189.x.
4. Peacock SJ. 2006. Melioidosis. Curr. Opin. Infect. Dis. 19:421-428. http://dx.doi.org/10.1097/01.qco.0000244046.31135.b3.
5. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl. Trop. Dis. 4:e900. http://dx.doi.org/10.1371/journal.pntd.0000900.
6. Currie BJ, Dance DA, Cheng AC. 2008. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1):S1-S4. http://dx.doi.org/10.1016/S0035-9203(08)70002-6.
7. Kanungo R, Padhan P, Bhattacharya S, Srimannarayana J, Jayanthi S, Swaminathan RP. 2002. Melioidosis-a report from Pondicherry, South India. J. Assoc. Physicians India 50:1438-1439.
8. Rolim DB, Vilar DC, Sousa AQ, Miralles IS, de Oliveira DC, Harnett G, O'Reilly L, Howard K, Sampson I, Inglis TJ. 2005. Melioidosis, northeastern Brazil. Emerg. Infect. Dis. 11:1458-1460. http://dx.doi.org/10.3201/eid1109. 050493.
9. Rolim DB, Rocha MF, Brilhante RS, Cordeiro RA, Leitao NP, Jr, Inglis TJ, Sidrim JJ. 2009. Environmental isolates of Burkholderia pseudomallei in Ceara State, northeastern Brazil. Appl. Environ. Microbiol. 75:1215-1218. http://dx.doi.org/10.1128/AEM.01953-08.
10. Mukhopadhyay C, Kaestli M, Vandana KE, Sushma K, Mayo M, Richardson L, Tuanyok A, Keim P, Godoy D, Spratt BG, Currie BJ. 2011. Molecular characterization of clinical Burkholderia pseudomallei isolates from India. Am. J. Trop. Med. Hyg. 85:121-123. http://dx.doi.org/10.4269/ajtmh.2011.11-0166.
11. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N. Engl. J. Med. 367:1035-1044. http://dx.doi.org/10.1056/NEJMra1204699.
12. Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, Currie BJ, Dance D, Gee JE, Larsen J, Limmathurotsakul D, Morrow MG, Norton R, O'Mara E, Peacock SJ, Pesik N, Paige Rogers L, Schweizer HP, Steinmetz I, Tan G, Tan P, Wiersinga WJ, Wuthiekanun V, Smith TL. 2012. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010 Emerg. Infect. Dis. Volume 18, number 2. http://wwwnc.cdc.gov/eid/article/ 18/12/12-0638-article.htm.
13. Inglis TJ, Rolim DB, Rodriguez JL. 2006. Clinical guideline for diagnosis and management of melioidosis. Rev. Inst. Med. Trop. Sao Paulo 48:1-4. http://dx.doi.org/10.1590/S0036-46652006000100001.
14. Peacock SJ, Schweizer HP, Dance DA, Smith TL, Gee JE, Wuthiekanun V, DeShazer D, Steinmetz I, Tan P, Currie BJ. 2008. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg. Infect. Dis. 14:e2. http://dx.doi.org/10.3201/eid1407.071501.
15. Campbell JW, Cronan JE, Jr. 2001. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55:305-332. http://dx.doi.org/10.1146/annurev.micro.55.1.305.
16. Heath RJ, White SW, Rock CO. 2001. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 40:467-497. http://dx.doi.org/10.1016/ S0163-7827(01)00012-1.
17. Heath RJ, White SW, Rock CO. 2002. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703. http://dx.doi.org/10.1007/s00253-001-0918-z.
18. Lu H, Tonge PJ. 2008. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res. 41:11-20. http://dx.doi.org/10.1021/ar700156e.
19. Zheng CJ, Sohn MJ, Kim WG. 2006. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae. J. Antibiot. (Tokyo) 59:808-812. http://dx.doi.org/10.1038/ja.2006.108.
20. Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, Jaworski DD, McManus E, Miller WH, Moore TD, Payne DJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Smith W, Takata DT, Vaidya KS, Yuan CC, Huffman WF. 2001. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 11:2061-2065. http://dx.doi.org/10.1016/S0960-894X(01)00404-8.
21. Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR, Jr, Sacchettini JC, Fidock DA. 2003. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. 278: 20851-20859. http://dx.doi.org/10.1074/jbc.M211968200.
22. Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE, Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF. 2002. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 45:3246-3256. http://dx.doi.org/10.1021/jm020050
23. Quemard A, Sacchettini JC, Dessen A, Vilcheze C, Bittman R, Jacobs WR, Jr, Blanchard JS. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241. http://dx.doi.org/10. 1021/bi00026a004.
24. Rawat R, Whitty A, Tonge PJ. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U. S. A. 100:13881-13886. http://dx.doi.org/10.1073/pnas.2235848100.
25. Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Jr, Sacchettini JC. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102. http://dx.doi.org/10.1126/science.279.5347.98.
26. Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE, Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF. 2003. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 46:1627-1635. http://dx.doi.org/10.1021/ jm0204035.
27. Slayden RA, Barry CE, III. 2002. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb.) 82:149-160. http://dx.doi.org/10.1054/tube. 2002.0333.
28. Slayden RA, Lee RE, Barry CE, III. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38:514-525. http://dx.doi.org/10.1046/j.1365-2958. 2000.02145.x.
29. England K, am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA. 2009. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. J. Antimicrob. Chemother. 64:1052-1061. http://dx.doi.org/10.1093/jac/dkp307.
30. Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ. 2009. Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol. 4:221-231. http://dx.doi.org/10.1021/cb800306y.
31. Andrew DP, Ruffing N, Kim CH, Miao W, Heath H, Li Y, Murphy K, Campbell JJ, Butcher EC, Wu L. 2001. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. J. Immunol. 166:103-111.
32. Gao Y, Qiu W, Tang Y, Yang Y, Zhang C, Fang X. 1999. Diagnosis and treatment of internal jugular phlebectasia (three cases report). Hua Xi Kou Qiang Yi Xue Za Zhi 17:352-354. (In Chinese.)
33. Massengo-Tiasse RP, Cronan JE. 2008. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase. J. Biol. Chem. 283:1308-1316.
34. Lu H, Tonge PJ. 2010. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei. Biochemistry 49:1281-1289. http://dx.doi.org/10.1021/bi902001a.
35. Liu N, Cummings JE, England K, Slayden RA, Tonge PJ. 2011. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. J. Antimicrob. Chemother. 66:564-573. http://dx.doi.org/10.1093/jac/dkq509.
36. Lopez CM, Rholl DA, Trunck LA, Schweizer HP. 2009. Versatile dualtechnology system for markerless allele replacement in Burkholderia pseudomallei. Appl. Environ. Microbiol. 75:6496-6503. http://dx.doi.org/10.1128/ AEM.01669-09.
37. DeShazer D, Brett PJ, Carlyon R, Woods DE. 1997. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J. Bacteriol. 179:2116-2125.
38. Mima T, Schweizer HP. 2010. The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob. Agents Chemother. 54: 3113-3120. http://dx.doi.org/10.1128/ AAC.01803-09.
39. Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ. 2006. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1:43-53. http://dx.doi.org/10.1021/ cb0500042.
40. Schweizer HP. 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol. 7:1389-1399. http://dx.doi.org/10.2217/fmb.12.116.
41. Parsons JB, Frank MW, Rosch JW, Rock CO. 2013. Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob. Agents Chemother. 57:5729-5732. http://dx.doi.org/10.1128/AAC.01038-13.